These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31919107)

  • 1. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.
    Levine AP; Chan MMY; Sadeghi-Alavijeh O; Wong EKS; Cook HT; Ashford S; Carss K; Christian MT; Hall M; Harris CL; McAlinden P; Marchbank KJ; Marks SD; Maxwell H; Megy K; Penkett CJ; Mozere M; Stirrups KE; Tuna S; Wessels J; Whitehorn D; ; ; Johnson SA; Gale DP
    J Am Soc Nephrol; 2020 Feb; 31(2):365-373. PubMed ID: 31919107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
    Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN.
    Meuleman MS; Vieira-Martins P; El Sissy C; Audard V; Baudouin V; Bertrand D; Bridoux F; Louillet F; Dossier C; Esnault V; Jourde-Chiche N; Karras A; Morin MP; Provot F; Remy P; Ribes D; Rousset-Rouviere C; Servais A; Thervet E; Tricot L; Zaidan M; Wynckel A; Zuber J; Le Quintrec M; Frémeaux-Bacchi V; Chauvet S
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1435-1445. PubMed ID: 37615951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
    Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
    Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
    J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C4d as a Diagnostic Tool in Proliferative GN.
    Sethi S; Nasr SH; De Vriese AS; Fervenza FC
    J Am Soc Nephrol; 2015 Nov; 26(11):2852-9. PubMed ID: 25991041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 Glomerulopathy.
    Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHR-5 Serum Levels and
    Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
    Front Immunol; 2021; 12():720183. PubMed ID: 34566977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical approach to primary membranoproliferative glomerulonephritis].
    Fakhouri F
    Nephrol Ther; 2016 Apr; 12 Suppl 1():S65-9. PubMed ID: 26972096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.
    Wong EK; Anderson HE; Herbert AP; Challis RC; Brown P; Reis GS; Tellez JO; Strain L; Fluck N; Humphrey A; Macleod A; Richards A; Ahlert D; Santibanez-Koref M; Barlow PN; Marchbank KJ; Harris CL; Goodship TH; Kavanagh D
    J Am Soc Nephrol; 2014 Nov; 25(11):2425-33. PubMed ID: 24722444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement dysregulation in glomerulonephritis.
    Kaartinen K; Safa A; Kotha S; Ratti G; Meri S
    Semin Immunol; 2019 Oct; 45():101331. PubMed ID: 31711769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of complement in C3 glomerulopathy.
    Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
    Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.
    Avasare RS; Canetta PA; Bomback AS; Marasa M; Caliskan Y; Ozluk Y; Li Y; Gharavi AG; Appel GB
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):406-413. PubMed ID: 29326307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.